Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Magle Chemoswed Holding

27,4

 

SEK

Mindre end 1K følgere

MAGLE

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
-4,86%
+1,48%
-12,18%
-21,26%
-17,47%
-15,1%
+20,65%
-
+36,36%

The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.

Læs mere
Markedsværdi
562,14 mio. SEK
Aktieomsætning
-
Omsætning
236,04 mio.
EBIT %
9,84 %
P/E
0,62
Udbytteafkast, %
-
Finanskalender
1.8
2025

Delårsrapport Q2'25

31.10
2025

Delårsrapport Q3'25

27.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Selskabsmeddelelse26.5.2025, 13.00

Bulletin from Annual General Meeting in Magle Chemoswed Holding AB (publ) held on the 26th of May 2025

Magle Chemoswed Holding
Selskabsmeddelelse22.5.2025, 07.56

Magle Chemoswed Holding Reports Financial Results For First Quarter 2025

Magle Chemoswed Holding
Selskabsmeddelelse5.5.2025, 15.30

Magle Chemoswed Holding AB (publ) Releases Annual Report for 2024.

Magle Chemoswed Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse27.4.2025, 16.30

Malmö, Sweden – Magle Group announces a revised publication date for its 2024 Annual Report, and its Q1 2025 Interim Report.

Magle Chemoswed Holding
Selskabsmeddelelse25.4.2025, 14.30

Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

Magle Chemoswed Holding
Pressemeddelelse25.4.2025, 07.00

Magle PharmaCept Partners with Pancreatic Cancer Europe PCE to Advance Innovation in Pancreatic Cancer Care

Magle Chemoswed Holding
Selskabsmeddelelse24.4.2025, 09.15

Magle Group Announces Acquisition of Saving Chlora AB

Magle Chemoswed Holding
Selskabsmeddelelse24.4.2025, 07.00

Notice of Annual General Meeting in Magle Chemoswed Holding AB (publ)

Magle Chemoswed Holding
Pressemeddelelse28.3.2025, 13.35

Magle Chemoswed Holding AB (publ): Magle Group to BioStock: We live by the mantra `earn it before you burn it'

Magle Chemoswed Holding
Pressemeddelelse27.3.2025, 12.28

Redeye: Magle Chemoswed Q4 - Delivering on its growth trajectory

Magle Chemoswed Holding
Selskabsmeddelelse27.3.2025, 07.30

Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

Magle Chemoswed Holding
Pressemeddelelse24.3.2025, 11.35

Magle Chemoswed Holding AB (publ): BioStock: Magle Group launches multicenter trial with pancreatic leakage indicator

Magle Chemoswed Holding
Pressemeddelelse19.3.2025, 07.15

Magle Group initiates Randomized Controlled Multicenter Trial with leading European university hospitals to explore SmartPAN® efficacy

Magle Chemoswed Holding
Selskabsmeddelelse26.2.2025, 17.00

Ingela Fritzson resigns from the Board of Directors of Magle Group

Magle Chemoswed Holding
Pressemeddelelse17.2.2025, 08.00

Magle Group is pleased to announce Magle PharmaCept’s participation in the DPC, German Pancreatic Club congress, set to take place February 27-March 1, 2025, in Heidelberg, Germany.

Magle Chemoswed Holding
Selskabsmeddelelse14.2.2025, 07.05

Magle Group Announces Revised Publication Date for Q4 2024 and Full-Year 2024 Reports Due to Ongoing Consolidation Process

Magle Chemoswed Holding
Selskabsmeddelelse9.1.2025, 20.45

Magle Group announces allocation in the directed share issue

Magle Chemoswed Holding
Selskabsmeddelelse30.12.2024, 11.30

Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB

Magle Chemoswed Holding
Selskabsmeddelelse20.12.2024, 14.30

Magle Group raises approximately SEK 36.8 million in the rights issue

Magle Chemoswed Holding
Selskabsmeddelelse16.12.2024, 14.30

Magle Group publishes supplementary prospectus

Magle Chemoswed Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team